Liraglutide Injection, Solution
Product Images NDC 0480-7250

Product Visual Gallery

This gallery contains 43 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 0480-7250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Liraglutide Injection A214568 1)

Chemical structure of liraglutide, depicted as a complex peptide chain with various functional groups and side chains. The structure illustrates the molecular connectivity and arrangement of atoms within liraglutide, corresponding to its role as the active ingredient in the injectable solution.*

FDA Label Image

C (Liraglutide Injection A214568 10)

An instructional illustration showing a close-up of hands manipulating the cap of a pen-style injector device. An arrow indicates the direction to remove or twist off the cap, demonstrating part of the preparation process for subcutaneous injection.*

FDA Label Image

D (Liraglutide Injection A214568 11)

An instructional illustration showing a hand holding a syringe or pen injector, with an arrow indicating the action of twisting or removing a cap from the device. The image is labeled with a letter "D" in the upper left corner, suggesting a step in a series of instructions.*

FDA Label Image

E (Liraglutide Injection A214568 12)

An instructional illustration showing a hand holding a syringe while inserting the needle cap, indicated by an arrow pointing toward the cap. The image appears to guide the proper assembly or handling step for a subcutaneous injection device.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 13)

Liraglutide 6 mg/mL injection, solution for subcutaneous use, labeled by Teva Pharmaceuticals, Inc. The package is a vial with a white cap and clear glass body displaying the solution inside. The label includes the product name 'Liraglutide' and other identifying text.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 14)

Liraglutide 6 mg/mL injection, solution in a subcutaneous delivery cartridge labeled by Teva Pharmaceuticals, Inc. The cartridge label displays the product name, strength, dosage form, and includes dosing instructions with a yellow highlight and a red circle marking a specific area on the cartridge.*

FDA Label Image

F (Liraglutide Injection A214568 15)

An instructional illustration showing a hand holding a syringe or pen injector, aligning the needle cap for removal indicated by a right-pointing arrow. The image is marked with a bold letter F in the upper left corner, suggesting it is part of a step-by-step guide.*

FDA Label Image

Flow Check Symbol (Liraglutide Injection A214568 16)

Liraglutide 6 mg/mL injection solution for subcutaneous use by Teva Pharmaceuticals, Inc. The image shows a carton with branding and dosage information visible but no additional details. The packaging is primarily white with black and grey text and graphics.*

FDA Label Image

G (Liraglutide Injection A214568 17)

An instructional illustration showing the dial of a Liraglutide injection pen with a dosage window displaying '0 mg'. An arrow indicates turning the dial knob. The image includes a label 'Flow Check Symbol selected' next to the dosage window reading '0'.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 18)

Liraglutide 6 mg/mL injection, solution for subcutaneous use in a single-dose vial. The packaging features a white and purple color scheme with the Teva Pharmaceuticals, Inc. logo prominently displayed. The carton contains the proprietary name, strength, dosage form, and route of administration.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 19)

Liraglutide 6 mg/mL injection, solution in a vial is shown. The label on the vial includes the proprietary name Liraglutide, the strength of 6 mg/mL, and the dosage form as a subcutaneous injection. The labeler is Teva Pharmaceuticals, Inc. The vial contains a clear solution.*

FDA Label Image

Figure 2 (Liraglutide Injection A214568 2)

Two cumulative frequency line graphs comparing body weight change percentage between Liraglutide (solid line) and placebo (dashed line) groups, with cumulative frequency on the y-axis and change in body weight percentage on the x-axis, based on ITT multiple imputation data.*

FDA Label Image

H (Liraglutide Injection A214568 20)

Illustration showing a hand holding a Liraglutide injection pen. The image includes a close-up of the pen's needle cap and an upward arrow indicating removal of the cap before use.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 21)

Liraglutide 6 mg/mL injection, solution in a brown glass vial with gray rubber stopper and metal cap, labeled by Teva Pharmaceuticals, Inc. The vial is designed for subcutaneous administration.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 22)

Liraglutide 6 mg/mL injection solution in a glass vial with a purple cap and purple label accents. The label includes the product name and strength, and indicates subcutaneous administration. The vial appears to be a single-dose container. Labeler is Teva Pharmaceuticals, Inc.*

FDA Label Image

I (Liraglutide Injection A214568 23)

An instructional illustration showing how to adjust the dosage on a Liraglutide injection pen. The dial is being turned to select the dose, displaying an example of 0.6 mg selected. The pen is held in two hands with arrows indicating the direction to turn the dose selector.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 24)

Liraglutide 6 mg/mL injection, solution for subcutaneous use, packaged in a carton containing 1 pen with 3 mL total volume. The label shows the product name Liraglutide and the concentration, with the labeler listed as Teva Pharmaceuticals, Inc. The carton is white with green and black text.*

FDA Label Image

J (Liraglutide Injection A214568 25)

An instructional illustration showing a close-up of a Liraglutide injection pen with a dose window indicating approximately 3 mg left in the cartridge. The image highlights the dosage indicator on the pen device.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 26)

Liraglutide 6 mg/mL injection, solution in a 3 mL prefilled pen cartridge. The packaging label shows it is for subcutaneous use and is manufactured by Teva Pharmaceuticals, Inc. The product NDC is 0480-7250.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 27)

Liraglutide 6 mg/mL injection, solution in a subcutaneous delivery form. Packaging shows a vial with a white cap and a gray label featuring the product name and strength. Manufactured by Teva Pharmaceuticals, Inc. The label includes product details typical of prescription drug vials.*

FDA Label Image

K (Liraglutide Injection A214568 28)

An instructional illustration showing a close-up of a liraglutide injection pen's dose counter. The image demonstrates an example dose with the counter stopped at zero and indicates 2.4 mg left on the dose window. A hand is shown adjusting the dose selector.*

FDA Label Image

L (Liraglutide Injection A214568 29)

An instructional diagram showing a hand holding a liraglutide injection pen in a vertical position with the needle pointing downward towards a surface, indicating the direction for use or preparation.*

FDA Label Image

Figure 3 (Liraglutide Injection A214568 3)

Two line graphs showing the percent change in body weight over 56 weeks comparing Liraglutide and placebo groups. The left graph represents a larger sample (N=2487 to 1244), with Liraglutide showing a weight reduction of up to -9.2% versus placebo around -3.0%. The right graph shows a smaller sample (N=423 to 212), with Liraglutide reducing weight by approximately -6.7% compared to placebo at about -1.7%. Both graphs indicate greater weight loss with Liraglutide over time versus placebo.*

FDA Label Image

M (Liraglutide Injection A214568 30)

An instructional illustration showing a hand holding a Liraglutide injection pen with an arrow indicating downward pressure on the top of the pen. A close-up inset displays the dosage window on the pen reading '0', indicating the start or reset of the dosing mechanism.*

FDA Label Image

N (Liraglutide Injection A214568 31)

An instructional illustration showing a hand holding a Liraglutide injection pen, with a speech bubble instructing to count slowly from 1 to 6 during injection. The image demonstrates the proper use technique for administering the subcutaneous injection.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 32)

FDA Label Image

I Symbol (Liraglutide Injection A214568 33)

Liraglutide 6 mg/mL injection solution for subcutaneous use. The label shows details including the brand name Liraglutide, the volume strength of 6 mg/mL, and manufacturer Teva Pharmaceuticals, Inc. The packaging indicates it is a human prescription drug with NDC 0480-7250.*

FDA Label Image

O (Liraglutide Injection A214568 34)

An instructional illustration showing a hand holding a prefilled injection pen in a vertical upward position, with an arrow pointing upward below the pen. The image demonstrates the correct orientation for preparing or administering a subcutaneous injection using the pen device.*

FDA Label Image

P (Liraglutide Injection A214568 35)

An instructional illustration showing a hand holding a syringe with a rotating cap or dial at the top. The image indicates a twisting motion with an arrow, likely demonstrating how to adjust or unlock a component of the syringe before use.*

FDA Label Image

Q (Liraglutide Injection A214568 36)

An instructional illustration showing a needle being inserted through a septum or rubber stopper on a vial or container, indicated by a downward arrow. The image appears to demonstrate the proper technique for accessing medication from the container.*

FDA Label Image

R (Liraglutide Injection A214568 37)

An instructional illustration showing hands removing a cap from a Liraglutide injection pen, indicating direction with an arrow. The image focuses on proper handling of the subcutaneous injection device labeled with an R in a circle.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 38)

Liraglutide 6 mg/mL injection solution carton for subcutaneous use. The front of the carton prominently displays the product name Liraglutide, the strength 6 mg/mL, and the dosage form as an injection solution. The labeler is identified as Teva Pharmaceuticals, Inc. Packaging appears to hold multiple single-use pen applicators for dosing.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 39)

Liraglutide 6 mg/mL injection solution packaged in a pen cartridge. The labeling includes the proprietary name Liraglutide, dosage strength, and administration route for subcutaneous injection. The product is distributed by Teva Pharmaceuticals, Inc. The pen cartridge packaging is designed for single-patient use under prescription.*

FDA Label Image

Figure 4 (Liraglutide Injection A214568 4)

Line graph depicting change in body weight percentage over weeks for Liraglutide versus Placebo groups. Weight change is shown from 12 weeks before through 56 weeks after treatment start, with Liraglutide group showing a greater decrease compared to Placebo. Patient numbers at each time point are listed below the graph for both groups.*

FDA Label Image

I Symbol (Liraglutide Injection A214568 40)

Liraglutide 6 mg/mL injection, solution in a vial. The vial features a clear liquid and includes labeling with dosage strength and route (subcutaneous). The label displays the Teva Pharmaceuticals, Inc. logo and branding with product identification and lot information.*

FDA Label Image

S (Liraglutide Injection A214568 41)

Instructional illustration showing a syringe with a needle cover being removed. The image depicts the process of pulling the needle cover off the syringe prior to use.*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 42)

Liraglutide 6 mg/mL solution for injection in a single-dose 3 mL glass vial with a rubber stopper and aluminum seal. The label indicates use for subcutaneous injection and shows the proprietary and nonproprietary name Liraglutide. The vial is manufactured by Teva Pharmaceuticals, Inc.*

FDA Label Image

Carton-5s (Liraglutide Injection A214568 43)

The packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) by Teva Pharmaceuticals, Inc. It contains 5 prefilled pens of 3 mL each for subcutaneous injection. The label indicates single patient use, storage instructions to refrigerate and not freeze, and compatibility with universal fit disposable pen needles. The design features text, usage instructions, and illustrations of the pen device and needle.*

FDA Label Image

Figure 5 (Liraglutide Injection A214568 5)

A line graph showing BMI SDS (body mass index standard deviation score) change from baseline over time since randomization in weeks for Liraglutide and placebo groups. The graph includes observed means with error bars representing standard error of mean, tracking patient numbers at several time points up to week 56 and follow-up (FAS-MI).*

FDA Label Image

Exclamation Symbol (Liraglutide Injection A214568 6)

Liraglutide 6 mg/mL injection solution in a vial. The label indicates it is for subcutaneous use and is manufactured by Teva Pharmaceuticals, Inc. The vial contains 1.8 mL of solution and includes product identifiers such as strength and labeler information.*

FDA Label Image

Pen And Needle Parts (Liraglutide Injection A214568 7)

An instructional diagram of a Liraglutide Injection pen device for subcutaneous use. The labeled parts include the pen cap, pen window, pen scale, dose selector, dose counter, dose button, notch, outer needle cap, inner needle cap, needle, protective tab, and flow check symbol, illustrating components and key features of the injection pen.*

FDA Label Image

A (Liraglutide Injection A214568 8)

An instructional illustration showing hands operating a liraglutide injection pen, with an arrow indicating the direction to pull or separate the pen components, likely demonstrating a step in preparing the subcutaneous injection device for use.*

FDA Label Image

B (Liraglutide Injection A214568 9)

An instructional diagram showing a close-up of a hand holding a pen-like device, possibly an injection pen, with a visible dosage window and adjustment dial. This image likely demonstrates how to hold or prepare the device for subcutaneous injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.